Article

Alcon IOP-lowering glaucoma treatment approved in EU

Alcon Laboratories’ brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL (Simbrinza) eye drop formulation have been approved by the European Commission to decrease elevated IOP in adult patients with open-angle glaucoma or ocular hypertension.

 

Basel, Switzerland-Alcon Laboratories’ brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL (Simbrinza) eye drop formulation have been approved by the European Commission to decrease elevated IOP in adult patients with open-angle glaucoma or ocular hypertension.

The treatment, administered with one drop into the affected eyes twice daily, combines the two therapies of brinzolamide and brimonidine for elevated IOP into one, multidose bottle.

“(The treatment) complements Alcon’s glaucoma portfolio by addressing a significant unmet patient need,” said Jeff George, global head of Alcon. “We are so pleased to introduce the only fixed-combination therapy without a beta-blocker to help more glaucoma patients manage their progressive eye condition.”

The launch of the treatment in the European Union will start in the United Kingdom in the third quarter of 2014, followed by other European markets later this year and in 2015. In the United States, the treatment was approved by the FDA and has been available in the market since 2013.

 

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.